News Center

Ambrx closes $45M round of financing

Aug 4, 2016 | News Press Releases
SAN DIEGO, Aug. 4, 2016 /PRNewswire/ -- Ambrx, Inc., a clinical stage biotechnology company that discovers and develops first-in-class and best-in-class optimized protein therapeutics known as bio-conjugates, today announced that it has closed...

Ambrx and Zhejiang Medicine Co. Ltd initiated ARX788 First-In-Human phase I clinical trial in cancer patients

Mar 21, 2016 | News Press Releases

SAN DIEGO, March 21, 2016 - Ambrx and Zhejiang Medicine Co. Ltd. (ZMC) announced today that they initiated First-In-Human phase I clinical trial with ARX788, Ambrx's most advanced internally developed...

Ambrx Announces New Chief Medical Officer

Nov 16, 2015 | News Press Releases
SAN DIEGO, Nov. 16, 2015  Ambrx today announced the appointment of Yong-Jiang Hei, M.D., Ph.D. as Chief Medical Officer (CMO) reporting directly to CEO, Tiecheng "Alex" Qiao. 

Ambrx Names Dr. Tiecheng Qiao as CEO, Dr. Feng Tian as CSO

Jun 19, 2015 | Press Releases
Ambrx Names Dr. Tiecheng Qiao as CEO, Dr. Feng Tian as CSO Executives Will Work With New Chinese Owners to Advance Technology and Product Pipeline San Diego, June 19, 2015 -- Ambrx,...

Chinese Consortium Enters into Agreement to Acquire Ambrx

May 25, 2015 | Press Releases
SHANGHAI, May 21, 2015 /PRNewswire/ -- A consortium (the “Consortium”) consisting of entities affiliated with Shanghai Fosun Pharmaceutical Group, HOPU Investments, China Everbright Limited’s healthcare...